FORWARD-LOOKING STATEMENTS

Size: px
Start display at page:

Download "FORWARD-LOOKING STATEMENTS"

Transcription

1

2 FORWARD-LOOKING STATEMENTS The statements made by Kensey Nash and its representatives in this presentation will include certain forward-looking statements, including financial forecasts, that are based on the current beliefs of management as well as assumptions made by and information currently available to management. Wherever possible, we will try to identify these forward-looking statements by using words such as believe, expect, anticipate and other similar expressions. These words are not, however, the exclusive means for identifying these statements. Please see Kensey Nash s recent SEC filings including our most recent Quarterly Report on Form 10-Q and Annual report on Form 10-K for a discussion of risks and uncertainties and other factors that could cause actual results in the remainder of the fiscal year or beyond to differ materially from those expressed in or implied by any of our forward looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this prospectus. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements. 2

3 INTRODUCTION TO KENSEY NASH CORPORATION Leader in Regenerative Medicine Leader in Biomaterial R&D and World Class Manufacturing Leader in Strategic Corporate Partnerships 3

4 OUR BUSINESS MODEL Our business model is unique from others in the medical device field. We do not sell our products directly to a hospital or physician. Instead we provide products and technologies to our customers and strategic partners who utilize their well established distribution networks in a wide variety of market segments. Our business growth initiatives are guided by the four basic strategies: 1. Invest In Our Core Technologies 2. Develop New Proprietary Biomaterials Products 3. Establish New Partnerships and Customers 4. Expand our Medical Products Manufacturing 4

5 TARGETING POTENTIAL MARKETS EXCEEDING $15 BILLION Conductive and Inductive Bone Repair market today exceed $1 Billion. Biologic surgical mesh market for Hernia Repair is projected to be over $500M in General Surgery Spine Wound Repair Sports Medicine Cartilage and tendon repair markets are expected to approach $5 Billion by $3 Billion potential Market WW for Actifit GI Sealants market estimated at $3 Billion. Antifouling Coatings may help address the >$1 Billion in hospitalization costs resulting from biofilms and adhesions. 5 Cardio Neuro Cardiovascular sealants market is projected to be over $800M today. Dura Repair Sealants and Scaffolds are a subset of the projected $1 Billion market opportunity for Sealants in 2015.

6 MARKET DYNAMICS Expanding due to favorable demographics, greater access to healthcare, growth in new & innovative technology in regenerative medicine. Worldwide cost impact on government budgets and a unfavorable regulatory environment, particularly in USA, are negative factors. 6

7 PARTNERS & CUSTOMERS Our products and technologies reach the marketplace through our partner s distribution channels. Our mutual success is dependent upon our ability to provide world class Innovation, Product Development, Manufacturing and Customer Service. 7

8 CORE CAPABILITIES We are a leading developer & manufacturer of specialized medical devices focused on regenerative medicine utilizing proprietary biomaterials technology and innovative mechanical devices. Biomaterials Products for Tissue Repair and Regeneration Innovative Devices and Tooling 8

9 2012(E) PRODUCT SALES BY MARKET General Surgery Other Cardiology 7% 7% 6% 24% Sports Medicine 22% 34% Spine CMF & Trauma

10 Foundation Expansion Areas Most Recent Metal & PEEK ECMs Ceramics Core Technologies Adhesives Specialized MFG Devices Polymers Collagen 10

11 NATURAL BIOMATERIALS Collagen Acid-soluble collagen (Type I) Native fibrous collagen (Type I) Fibrillar Collagen (Type I) Powders, gels, sponges and structural matrices Composites Ceramic Combinations Biomaterial Mixtures Decellularized Tissues Dermis ECM Mesothelium ECM 11

12 RESORBABLE SYNTHETIC BIOMATERIALS Variety of Resorbable Materials PLA, PGA, Polycarbonates (e.g. TMC) Polycaprolactones Multiple Configurations Solid, Porous and High Strength Composites Ceramics Combinations B-TCP HA Bioactive Glass 12

13 METALS, PEEK, CERAMICS Non Resorbable Polymers PEEK Polyurethane Metals Titanium Stainless Steel Ceramics Calcium Salts (Beta-TCP, HA, blends, etc.) Composites 13

14 Near Term GROWTH DRIVERS Long Term ECM Products Surgical Adhesives Norian & Bone Repair Research Pipeline Partnership Dynamics Proprietary Processes J&JSYNTHES

15 ECM XENOGRAFT TISSUE PROCESSING Experience >18 Years Processing >20 Million Collagen Implants Accomplished Scientific Staff Proprietary OPTRIX Process Not just collagen Preserve extracellular matrix & architecture and beneficial biomolecules Broad portfolio and applications targeting multiple markets 15 OPTRIX Process

16 KNC S OPTRIX PROCESS ATTRIBUTES Optrix is Gentle Maintains Native Collagen Scaffold High Strength, No Crosslinking Optrix is Selective Removes Antigens Maintains Beneficial Components 16

17 ECM PRODUCT PORTFOLIO Proprietary OPTRIX Processing Porcine Dermis, Medeor Matrix Lyophilized or Pre-Hydrated Where high strength is vital Large sizes, single layer Multiple thicknesses available Porcine Mesothelium, Meso BioMatrix Where both strength & suppleness are vital Large sizes, single layer Bi-phasic architecture (basal lamina) Unique regenerative capabilities 17 Others

18 KNC S ECM PRODUCT PORTFOLIO DX Reinforcement Biologic Matrix 18

19 KNC S ECM PRODUCT PORTFOLIO DX Reinforcement Biologic Matrix Unpartnered Meso BioMatrix Surgical Mesh Unpartnered 19 Medeor Matrix Surgical Mesh

20 KNC S ECM PRODUCT PORTFOLIO Unpartnered Meso BioMatrix Dura, Dental, Cardio DX Reinforcement Biologic Matrix Unpartnered Meso BioMatrix Surgical Mesh Unpartnered Unpartnered 20 Meso BioMatrix Wound Medeor Matrix Surgical Mesh

21 SIGNIFICANT MARKET OPPORTUNITIES 3 rd gen Bone Dermis Mesothelium Intestine Tendon Blood Vessel Nerve Muscle Organ Not just one product, but a technology foundation for an entire business, yielding various partners & products in multiple markets. 21

22 2011 PRODUCT AND TECHNOLOGY INVESTMENTS $50 Million+ in Acquisitions/Investments Manufacturing Rights and Technology Norian s Orthobiologic Bone Repair Products Orteq s Sports Medicine Product Nerites Technology Platform Adhesives Sealants Coatings 22

23 CERAMIC AND NORIAN RELATED TECHNOLOGY chronos TCP Preforms are synthetic porous resorbable ceramic bone graft materials composed of ß-tricalcium phosphate, which serve as a temporary bone substitute to fill and bridge boned defects. Norian Bone Cements are a family of calcium phosphate and sodium phosphate based cements that are available as a moldable fast setting putty (FSP) or as an injectable prepared with a specialized rotary mixer. Key product lines include the Norian Skeletal Repair System (SRS) and Norian Cranial Repair System (CRS). 23 SynPOR is a family of non absorbable and biocompatible semi-rigid implants manufactured from Porous Polyethylene (UHMWPE) which are well suited for craniofacial reconstruction and augmentation including orbital floor/wall and rim procedures.

24 CERAMIC AND NORIAN RELATED TECHNOLOGY chronos Strip is an osteoconductive synthetic bone void filler manufactured from chronos beta-tricalcium phosphate (TCP) granules and polylactide caprolactone. The product is indicated for bony voids or gaps not intrinsic to the stability of the bony structure and for use in the treatment of bony defects. Norian Delivery Syringe and Needles provide an easy and precise way to inject the Norian SRS, CRS, Drillable and Reinforced bone void fillers. chronos Bone Marrow Aspiration System is indicated for aspirating bone marrow, which when used in combination with the chronos materials, can serve to accelerate and enhance osteointegration and therefore serve as an alternative to allogenic bone graft material. 24

25 SPORTS MEDICINE INVESTMENT KNC s $5M Investment In Orteq Exclusive WW manufacturing rights Approximate 10% ownership Transfer price and royalties Actifit Synthetic Meniscal Scaffold Arthroscopic option for treatment of irreparable partial meniscal tears Two Year clinical Data Vascular and cellular ingrowth Significant pain relief Increased functionality CE Approved, IDE filed in September,

26 ADHESIVE TECHNOLOGY ACQUISITION Nerites Corporation Assets: Price = $20M Surgical adhesive & sealant technology Sticks to tissue and biomaterials Adheres in wet environments Flexible, strong & durable Convenient and easy to use Applications in multiple clinical procedures Opportunities for new markets and partners Synergistic with KNC core biomaterial technologies (e.g. ECM, collagen, polymer, etc.) 26

27 KNC MARKETS DRIVING GROWTH Foundation Recent Focus Area Future Orthopaedic Structural Implants for Spine and Trauma Bone/Joint Cartilage & Meniscus Repair General Surgery Hernia Repair, Breast Recon., Orafacial & Bariatric Neurosurgery Dura, Peripheral Nerve UroGynecology Pelvic Floor Repair Cardiovascular Sports Medicine Tendon/Ligament Fixation and Regeneration Bone Substitutes Non Load Bearing Spine & Trauma Dental Barrier Membranes & Bone Augmentation 27

28 STRONG PIPELINE DRIVES FUTURE GROWTH General Surgery Sports Med Spine Neuro Timeline 28 Wound Repair 2016 Potential Incremental Revenue ($M) ECM Dermis: Hernia Breast Reconstruction (Synthes) ECM Dermis: OBGYN (open) ECM Meso Breast Reconstruction (open) Antifouling (open) ECM Tendon (Arthrex) Generation II Coatings(open (Open) FY12 FY13 FY14 Next Generation Hernia Cartilage CRD OUS (Arthrex) Cell Scaffolds (open) Meniscus Repair (Orteq) Generation II Cell Therapy (open)(extraction, Processing) Gen II Next Gen Bone Repair (Stryker) ECM Bone Repair (open) Norian Products (Synthes) Next Generation Norian Products Cell Therapy (open)(extraction, Processing) Gen II ECM Powders, Dressings (Open) Inductive Bone Repair FY15 $75 $115M Dura Adhesive (open) Dura Scaffold (open) FY16

29 FINANCIALS 29

30 FY12 FINANCIAL SNAPSHOT Core Bio Sales Q1 (9/30/11) Q2 (12/31/11) $13.6M $12.8M YOY Growth 121% 96%* * Q2 Core Biomaterials growth (excluding acquisitions) of 26%. FY12 Q3 (3/31/12) Guidance Core Bio Sales - $13.4M to $13.6M YOY Growth- 56% to 58% * EPS of $0.22 to $0.24 ** * Core Biomaterials growth (excluding acquisitions) of 16%. **Negatively impacted by $2.5M or $0.20 per share due to reduced SJM royalty rate. 30 See proforma notes at end of presentation

31 STRONG BALANCE SHEET AND CASH FLOW Balance Sheet 12/31/11 Cash $32.8M; Working Capital $41.7M $35M Credit Facility $0.25 per share quarterly dividend declared- Jan 3, 2012 Cash Flow 6/30/11 Operating Cash Flow $20M+ Cash used for acquisitions/investments $32M Cash used for stock repurchases $30M ($115M over last 3 yrs. +) 31 * See proforma notes at end of presentation

32 PROFORMA ADJUSTMENTS FY 2011 Excludes $18.2 million or $1.34 of acquired in-process R&D charges related to the acquisition of Nerites. FY 2012 Excludes the impact of $0.08 related to step-up in inventory values required under acquisition accounting resulting from the acquisition of Norian. 32

33 SUMMARY Broad Portfolio of Regenerative Medicine Products Diverse & Growing Markets exceeding $15B in Orthopaedics, Sports Medicine, General Surgery, Cardiovascular Expanding Strategic Corporate Partnerships Three New Foundation Businesses in regenerative medicine with ECM, Norian & Adhesives Poised for strong biomaterials sales growth in FY12 and long- term profit growth. Strong balance sheet and cash flow 33

34 SUMMARY Kensey Nash seeks to improve lives through all we do. Through relationships that partner innovation with inspiration. 34

35 SUMMARY Kensey Nash seeks to improve lives through all we do. Through technologies that enhance capabilities and expertise. 35

36 SUMMARY Kensey Nash seeks to improve lives through all we do. And through the guiding principle that our solutions must help the body heal itself. 36

37 TM